130 related articles for article (PubMed ID: 15867944)
1. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.
Ghuysen A; Dogné JM; Chiap P; Rolin S; Masereel B; Lambermont B; Kolh P; Tchana-Sato V; Hanson J; D'Orio V
Cardiovasc Drug Rev; 2005; 23(1):1-14. PubMed ID: 15867944
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.
Dogné JM; Rolin S; de Leval X; Benoit P; Neven P; Delarge J; Kolh P; Damas J; David JL; Masereel B
Cardiovasc Drug Rev; 2001; 19(2):87-96. PubMed ID: 11484064
[TBL] [Abstract][Full Text] [Related]
4. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
Ghuysen A; Lambermont B; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Magis D; Hanson J; Segers P; D'Orio V
J Pharmacol Exp Ther; 2004 Sep; 310(3):964-72. PubMed ID: 15121765
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
Dogné JM; Hanson J; de Leval X; Kolh P; Tchana-Sato V; de Leval L; Rolin S; Ghuysen A; Segers P; Lambermont B; Masereel B; Pirotte B
J Pharmacol Exp Ther; 2004 May; 309(2):498-505. PubMed ID: 14742735
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor.
Dogné JM; Wouters J; Rolin S; Michaux C; Pochet L; Durant F; Delarge J; Masereel B
J Pharm Pharmacol; 2001 May; 53(5):669-80. PubMed ID: 11370706
[TBL] [Abstract][Full Text] [Related]
7. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
Rolin S; Petein M; Tchana-Sato V; Dogne JM; Benoit P; Lambermont B; Ghuysen A; Kolh P; Masereel B
J Pharmacol Exp Ther; 2003 Jul; 306(1):59-65. PubMed ID: 12721335
[TBL] [Abstract][Full Text] [Related]
8. Thromboxane A2 receptor antagonism in man and rat by a sulphonylcyanoguanidine (BM-144) and a sulphonylurea (BM-500).
Masereel B; Damas J; Fontaine J; Lembege M; Lacan F; Nuhrich A; Delarge J; Pochet L; Dogne JM
J Pharm Pharmacol; 1999 Jun; 51(6):695-701. PubMed ID: 10454046
[TBL] [Abstract][Full Text] [Related]
9. Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function.
Dogné JM; de Leval X; Neven P; Rolin S; Wauters J; David JL; Delarge J; Massereel B
Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):311-7. PubMed ID: 10883063
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors.
Rolin S; Dogne JM; Vastersaegher C; Hanson J; Masereel B
Prostaglandins Other Lipid Mediat; 2004 Oct; 74(1-4):75-86. PubMed ID: 15560117
[TBL] [Abstract][Full Text] [Related]
11. Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles.
Rolin S; Dogné JM; Michaux C; Delarge J; Masereel B
Prostaglandins Leukot Essent Fatty Acids; 2001 Aug; 65(2):67-72. PubMed ID: 11545621
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function.
Dogné JM; de Leval X; Kolh P; Sanna V; Rolin S; Michaux C; Mauer M; David JL; Masereel B; Pirotte B
Prostaglandins Leukot Essent Fatty Acids; 2003 Jan; 68(1):49-54. PubMed ID: 12538090
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion.
Kolh P; Rolin S; Tchana-Sato V; Pétein M; Ghuysen A; Lambermont B; Hanson J; Magis D; Segers P; Masereel B; D'Orio V; Dogne JM
Prostaglandins Other Lipid Mediat; 2006 Mar; 79(1-2):53-73. PubMed ID: 16516810
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis.
Olson RW; Dotson R; Mathis J; Cohen DS; Webb RL
Eur J Pharmacol; 1993 May; 236(1):75-87. PubMed ID: 8319746
[TBL] [Abstract][Full Text] [Related]
17. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
[TBL] [Abstract][Full Text] [Related]
18. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
[TBL] [Abstract][Full Text] [Related]
19. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro.
O'Keefe EH; Liu EC; Greenberg R; Ogletree ML
Prostaglandins; 1985 May; 29(5):785-97. PubMed ID: 3925501
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of [[(benzenesulfonamido)alkyl]phenyl]alkanoic acid derivatives containing pyridyl or imidazolyl groups and their thromboxane A2 receptor antagonistic and thromboxane A2 synthase inhibitory activities.
Sakurai S; Ogawa N; Suzuki T; Kato K; Ohashi T; Yasuda S; Kato H
Chem Pharm Bull (Tokyo); 1996 Aug; 44(8):1510-20. PubMed ID: 8795270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
